| scholarly article | Q13442814 |
| P356 | DOI | 10.4049/JIMMUNOL.171.8.4028 |
| P953 | full work available at URL | https://journals.aai.org/jimmunol/article-pdf/171/8/4028/1173324/4028.pdf |
| P698 | PubMed publication ID | 14530323 |
| P5875 | ResearchGate publication ID | 9062833 |
| P50 | author | Robert F. Siliciano | Q7344216 |
| Simon F Lacey | Q56978267 | ||
| Corinna La Rosa | Q90615813 | ||
| Don J. Diamond | Q37374385 | ||
| P2093 | author name string | Pirouz Daftarian | |
| Saima Ali | |||
| Rahul Sharan | |||
| Jeff Longmate | |||
| Christopher Buck | |||
| P2860 | cites work | A Toll-like receptor recognizes bacterial DNA | Q24290668 |
| Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization | Q24655648 | ||
| Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization | Q24670153 | ||
| Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus | Q28302762 | ||
| Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone | Q29547734 | ||
| Degradation signals in the lysine-asparagine sequence space | Q30804927 | ||
| Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries | Q30982884 | ||
| HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. | Q44368205 | ||
| Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection | Q44519261 | ||
| Ubiquitin fusion technique and its descendants | Q44668356 | ||
| Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). | Q45012988 | ||
| HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides | Q45151315 | ||
| Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes | Q45730520 | ||
| A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques | Q45734404 | ||
| Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus. | Q45736575 | ||
| Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors | Q45747345 | ||
| A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group | Q45748181 | ||
| CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus | Q45754574 | ||
| In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine | Q45844272 | ||
| Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses | Q45847515 | ||
| Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites | Q46223733 | ||
| Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles | Q47564568 | ||
| Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. | Q47567558 | ||
| A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. | Q52546140 | ||
| Oral administration of an antigenic synthetic lipopeptide (MAP-P3C) evokes salivary antibodies and systemic humoral and cellular responses. | Q53734262 | ||
| Temporal loss of Nef-epitope CTL recognition following macaque lipopeptide immunization and SIV challenge | Q56901468 | ||
| Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques | Q57089572 | ||
| HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals | Q57997711 | ||
| HIV-specific cytotoxic T lymphocytes in seropositive individuals | Q59098667 | ||
| HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals | Q69022796 | ||
| Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants | Q73067785 | ||
| H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies | Q73129213 | ||
| Mechanisms of cytokine synergy essential for vaccine protection against viral challenge | Q74114711 | ||
| A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery | Q74261393 | ||
| Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice | Q74535840 | ||
| Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques | Q116178928 | ||
| CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice | Q33597242 | ||
| Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual | Q33671780 | ||
| Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine | Q33797285 | ||
| Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif | Q33836117 | ||
| Relative dominance of epitope-specific cytotoxic T-lymphocyte responses in human immunodeficiency virus type 1-infected persons with shared HLA alleles | Q33842771 | ||
| Adjuvants designed for veterinary and human vaccines | Q34189235 | ||
| Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans | Q34195888 | ||
| Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. | Q34323839 | ||
| Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes | Q34340988 | ||
| Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection | Q34354995 | ||
| Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs | Q34355633 | ||
| Immunologic and proteolytic analysis of HIV-1 reverse transcriptase structure | Q34558243 | ||
| Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge | Q35884740 | ||
| High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection | Q36043015 | ||
| CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects | Q36166987 | ||
| Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1 | Q36363763 | ||
| Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection | Q36369054 | ||
| Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. | Q36377141 | ||
| CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity | Q36380885 | ||
| Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection | Q36576849 | ||
| Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence | Q36597984 | ||
| A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity | Q36770993 | ||
| Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides | Q37610962 | ||
| An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein | Q37644137 | ||
| Reduction of respiratory syncytial virus titer in the lungs of mice after intranasal immunization with a chimeric peptide consisting of a single CTL epitope linked to a fusion peptide | Q39081608 | ||
| CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses | Q40776605 | ||
| Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine | Q40811278 | ||
| Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response. | Q40855997 | ||
| Adjuvants--a balance between toxicity and adjuvanticity | Q40883098 | ||
| Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. | Q40889921 | ||
| The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. | Q41111519 | ||
| Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein | Q41665138 | ||
| Vaccination to treat persistent viral infection | Q41723256 | ||
| Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism | Q41734956 | ||
| HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice | Q41903577 | ||
| Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors | Q42029476 | ||
| Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion | Q42818707 | ||
| Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. | Q42833971 | ||
| Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. | Q43429538 | ||
| HIV-1-specific cellular immune responses among HIV-1-resistant sex workers | Q44139088 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunology | Q101929 |
| Vaccinia virus | Q1986297 | ||
| immunization | Q1415366 | ||
| P304 | page(s) | 4028-4039 | |
| P577 | publication date | 2003-10-01 | |
| 2003-10-15 | |||
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge | |
| Immunization with Th-CTL Fusion Peptide and Cytosine-Phosphate-Guanine DNA in Transgenic HLA-A2 Mice Induces Recognition of HIV-Infected T Cells and Clears Vaccinia Virus Challenge | |||
| P478 | volume | 171 |
| Q36824066 | A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. |
| Q50425077 | Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10. |
| Q30350301 | CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications. |
| Q45417971 | Cross-reactive CTL recognizing two HLA-A*02-restricted epitopes within the BK virus and JC virus VP1 polypeptides are frequent in immunocompetent individuals |
| Q33930455 | Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides. |
| Q36194073 | HLA class I transgenic mice: development, utilisation and improvement |
| Q35784663 | HLA-A2-restricted protection against lethal lymphocytic choriomeningitis |
| Q35024149 | Identification of protective Lassa virus epitopes that are restricted by HLA-A2. |
| Q46335945 | Immunostimulatory CpG oligodeoxynucleotides enhance the induction of bovine CD4+ cytotoxic T-lymphocyte responses against the polymorphic immunodominant molecule of the protozoan parasite Theileria parva |
| Q33611645 | Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy |
| Q37155744 | Mamu-A01/K(b) transgenic and MHC Class I knockout mice as a tool for HIV vaccine development |
| Q37736005 | Mucosal HIV vaccines: a holy grail or a dud? |
| Q35953762 | Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines |
| Q33887085 | Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits |
| Q43673917 | Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. |
| Q34660422 | Oral vaccination: where we are? |
| Q42957161 | Protection against vaccinia virus challenge by CD8 memory T cells resolved by molecular mimicry. |
| Q37208345 | Protective immunity with an E1 multivalent epitope DNA vaccine against cottontail rabbit papillomavirus (CRPV) infection in an HLA-A2.1 transgenic rabbit model |
| Q34077543 | The influence of delivery vectors on HIV vaccine efficacy |
| Q34730757 | Vaccine generated immunity targets an HPV16 E7 HLA-A2.1-restricted CD8(+) T cell epitope relocated to an early gene or a late gene of the cottontail rabbit papillomavirus (CRPV) genome in HLA-A2.1 transgenic rabbits |
| Q35751946 | Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. |
Search more.